Abstract. Fatty acid synthase (FAS) is the key enzyme regulating de novo biosynthesis of fatty acids. FAS overexpression has been found in many types of tumors and is associated with poor survival. However, the expression of FAS and its relationship with prognosis in Chinese patients with gastric carcinoma are still unknown. Therefore, in this study, we examined the expression of FAS using tissue microarrays and determined its correlation with clinicopathological characteristics and prognosis of gastric carcinoma in Chinese patients. FAS overexpression was graded as S (T/A) <1, ≥1 to <2, ≥2 to <3 or ≥3 in 35 (38.9%), 20 (22.2%), 9 (10%) and 26 (28.9%) patients, respectively. High FAS overexpression [S (T/A) ≥3] was significantly correlated with poor prognosis (log-rank test, P= 0.0078) and with decreased 3-year survival rate (χ 2 test, P=0.0023). FAS overexpression was not significantly associated with other clinicopathological characteristics. In conclusion, our results suggest that FAS expression might be a potential prognostic marker for gastric carcinoma in Chinese patients.
Introduction
Fatty acids (FAs) are biological molecules with important physiological roles in energy storage, membrane formation and protein acylation (1) . Animals acquire FAs from the diet and via de novo biosynthesis (2) . In the latter, FAs are predominantly generated by a 250-to 270-kDa multifunctional and homodimeric enzyme, fatty acid synthase (FAS). Long-chain FAs, the main product of FAS, are derived from acetyl-CoA, malonylCoA and NADPH (3) . FAs are essential constituents of biological membranes and are important substrates in energy metabolism. Although the mechanisms responsible for FAS overexpression in tumors are not fully understood, the PTEN/PI3K/AKT and RAS/RAF/MAPK/ERK1/2 pathways are known to regulate FAS expression (3, 4) , and these pathways are often hyperactive in tumors. Notably, in the LNCaP prostate cancer cell line, pharmacological inhibition of PI3K or reintroduction of wild-type PTEN was found to reduce FAS expression (4) .
Most tissues, except for the liver, adipose tissue, cycling endometrium (5), fetal lungs (6), lactating breast (7, 8) and embryos (3, 9) utilize dietary FAs to build new structural lipids. Therefore, FAS is expressed at low levels in most normal tissues. By contrast, in cancer tissues, the FA supply is highly dependent on de novo biosynthesis via FAS. Indeed, several studies have shown that FAS is overexpressed in many cancers, including breast (10, 11) , prostate (12, 13) , ovarian (14) and colorectal carcinomas (15, 16) . Furthermore, high FAS expression is associated with advanced clinical stage, poor differentiation and poor prognosis of breast (10), prostate (17) and ovarian carcinomas (15) . Downregulation of FAS by RNAi was found to inhibit growth and apoptosis in LnCaP cells but not in normal fibroblasts (18) . Furthermore, pharmacological or RNAi-mediated downregulation of FAS significantly sensitized the responsiveness of breast cancer cell lines (SK-Br3, MCF-7 and MDA-MB-231) to paclitaxel or vinorelbine (19, 20) . These results indicate that FAS is an important prognostic factor in certain types of cancers and may represent a potential therapeutic target for cancer chemotherapy. 
Materials and methods
Patients and tissue samples. Ninety patients with gastric carcinoma who underwent surgery between 2007 and 2008 were enrolled in this study. None of the patients had received any treatment before surgery. We obtained complete clinicopathological information for all patients, including age, gender, tumor size, histological grade, AJCC tumor stage, depth of invasion, lymph node metastasis and distant metastasis. All of the patients included in this study had adenocarcinoma. The median age of the patients at the time of diagnosis was 65.5 years (range 34-83 years). The histological grade of the tumor was evaluated based on the degree of tumor differentiation, tumor necrosis and mitotic count, according to the criteria of Enzinger and Weiss (23) . Follow-up time was calculated as the time from initial surgery to the death of the patient due to the primary tumor or the date of last contact. Tumor tissue and paired adjacent normal tissue samples were obtained at surgery. All tissues were dissected in the operating room, immediately frozen, and stored at -80˚C. Informed consent for use of tissue samples in future molecular studies was obtained from each patient. This study was approved by the Ethics Committee of the Third Xiangya Hospital, Central South University (Hunan, China). Clinical and treatment information was extracted by chart review carried out by the surgeon with approval from our institutional review board.
Tissue microarray (TMA) preparation. Core needle biopsies (1.5 mm diameter) were extracted from paraffin-embedded tissue samples, and mounted into a recipient paraffin block using a dedicated tissue array instrument (Beecher Instruments, Sun Prairie, WI, USA). Then, 4-µm-thick sections of the TMA were cut, transferred to glass slides and stained with hematoxylin and eosin.
Immunohistochemistry. TMA sections (1.5-mm diameter; 4-µm thick) from archival, formalin-fixed, paraffin-embedded tissue specimens were mounted on poly-L-lysine (Muto Chemicals, Tokyo, Japan)-coated slides. The TMA sections were deparaffinized in xylene for 15 min, rehydrated in an ethanol gradient and heated at 95˚C for 5 min in 10 mM sodium citrate buffer (pH 6.0) in a microwave oven for antigen retrieval. Endogenous peroxidase was inactivated by incubating the sections in 3% H 2 O 2 for 15 min at room temperature. The sections were blocked in 3% normal donkey serum and incubated at 4˚C overnight with monoclonal anti-FAS antibody (dilution, 1:50; no. 3180S, Cell Signaling Technology, Danvers, MA, USA), antipERK1/2 antibody (dilution, 1:1000; no. 4370, Cell Signaling Technology) and anti-PTEN antibody (dilution, 1:50; no. 9559C, Cell Signaling Technology). Finally, the sections were stained with horseradish peroxidase-conjugated donkey antirabbit IgG (H+L) secondary antibody (711-035-152, Jackson ImmunoResearch Europe, Newmarket, UK). Signal detection was carried out using a Dako signaling amplification system (K346811; Dako, Glostrup, Denmark). The TMA sections were counterstained with hematoxylin, dehydrated, and mounted.
TMA score. Immunohistochemistry was scored based on staining intensity and the percentage of positive cells. The staining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; and 3, high intensity. The immunoreactive score was calculated as staining intensity score x percentage of FAS-positive cells. We also calculated S (T/A), immunoreactive score of tumor tissue/immunoreactive score of paired adjacent normal tissue, as an index for the difference in expression between tumor and normal tissue. FAS immunostaining was analyzed under a microscope (Nikon Eclipse E600) and estimated independently by two pathologists.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, Fisher's exact test was used. Survival was estimated using the Kaplan-Meier method, and differences in survival curves were determined using the log-rank test. Values of P<0.05 were regarded as statistically significant. Table I TMA and immunohistochemistry. A representative TMA stained for FAS is shown in Fig. 1A . No signal was detected in the nuclei or on the cell membrane, indicating that FAS was mainly localized to the cytoplasm. The mean immunohistochemical score of FAS expression was significantly higher in tumor tissue than in adjacent normal tissue (1.065±0.099 vs. 0.798±0.074, P<0.05, Fig. 2A ). These data indicate that FAS was overexpressed in the cytoplasm in tumor tissue compared to the expression in the adjacent normal tissue. To investigate the difference in expression between tumor tissues and normal tissues, we calculated S (T/A) as described in Materials and methods. Representative tissue sections corresponding to S (T/A) ≥1 to <2 (low), S (T/A) ≥2 to <3 (medium) and S (T/A) ≥3 (high expression) are shown in Fig. 1B . Overall, 38.9% (35/90), 22 .2% (20/90), 10% (9/90) and 28.9% (26/90) of the carcinoma tissue specimens were classified as S (T/A) ≥0 to <1, S (T/A) ≥1 to <2, S (T/A) ≥2 to <3 and S (T/A) ≥3, respectively (Fig. 2B) .
Results

Clinicopathological characteristics.
Relationship between FAS overexpression and clinicopathological parameters.
To investigate the association between FAS overexpression and clinicopathological parameters, three grades of FAS overexpression (S (T/A) ≥1, ≥2 and ≥3) were established. FAS overexpression was not significantly associated with any of the clinicopathological variables recorded, including age, gender, grade, tumor size and lymph node metastasis (Table II) . As several reports have shown that FAS expression is modulated by the PTEN/PI3K/AKT and RAS/ RAF/MEK/ERK pathways, we determined the expression of several components in these two pathways (4, 24) . Surprisingly, FAS overexpression was not significantly correlated with total, cytoplasmic or nuclear loss of PTEN (Table II) or pERK expression (data not shown) in gastric carcinomas.
Survival analysis. Finally, we conducted survival analysis to determine whether FAS overexpression in tumors was associated with survival by plotting Kaplan-Meier survival curves and calculating the 3-year survival rate for all three grades of FAS overexpression. For cases with S (T/A) ≥1 or ≥2, FAS overexpression was not associated with overall survival or 3-year survival rate (Table III ; Fig. 3A and B) . However, among cases with S (T/A) ≥3, FAS overexpression was significantly associated with poor survival (Fig. 3C , log-rank test, P=0.0078) and with a decreased 3-year survival rate (Table III; χ 2 test, P=0.0023).
Discussion
FAS protein, also known as oncogenic antigen 519 (OA-519), is overexpressed and hyperactivated in the majority of human malignancies. It plays a central role in the maintenance of the malignant phenotype by enhancing cancer cell survival and proliferation (3) . Overexpression of FAS has been reported in human carcinomas including prostate, ovary, breast, colon, endometrium, thyroid gland, squamous cell carcinoma of the lung, and gastric carcinomas. In this study, FAS overexpression was detected in 22.2% (20/90), 10% (9/90) and 28.9% (26/90) of the carcinoma tissue specimens graded as S (T/A) ≥1 to <2, S (T/A) ≥2 to <3 and S (T/A) ≥3, respectively.
Many studies have revealed that FAS overexpression and hyperactivity is regulated by the MAPK/ERK1/2 and PTEN/PI3K/AKT signaling pathways. Therefore, we examined PTEN and pERK expression levels in the same TMA samples. However, FAS overexpression was not correlated with pERK expression or the loss of PTEN in these gastric carcinoma specimens. These findings suggest that there are signaling pathways independent of the PTEN/PI3K/AKT and RAS/RAF/MEK/ERK pathways, such as the ubiquitin-protease pathway, that regulate FAS expression (25) .
Although FAS overexpression at any of the three levels defined in this study was not associated with any of the clinicopathological parameters assessed (age, gender, AJCC stage and histological grade), high FAS overexpression [S (T/A) ≥3] was significantly associated with poor survival and with a reduced 3-year survival rate. Although several studies have reported that FAS is overexpressed in gastric cancer (21, 22) , to our knowledge, our study is the first to show that high FAS overexpression could be a prognostic marker in gastric carcinoma.
In addition to its potential utility as a prognostic marker for cancer patients, FAS shows some promise as a chemotherapeutic target (3, (26) (27) (28) . For example, several studies have shown that cerulenin, a specific noncompetitive inhibitor of the β-ketoacyl synthase activity of FAS, is selectively cytotoxic to breast and ovarian cancer cells exhibiting enhanced fatty acid synthesis, but not to normal cells with constitutively low FAS expression (29, 30) . Based on these and other results, more research into the clinical relevance of FAS overexpression is necessary, particularly because FAS may represent an excellent target for treating gastric carcinoma, and other tumors. 
